Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
August-2014 Volume 10 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
August-2014 Volume 10 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Generation of transgenic fibroblasts expressing pancreas‑specific and doxycycline-inducible ICER Iγ for the establishment of a porcine model of human diabetes mellitus

  • Authors:
    • Hee Young Kang
    • Eui-Man Jung
    • Eui-Ju Hong
    • Sang-Hwan Hyun
    • Woo-Suk Hwang
    • Eui-Bae Jeung
  • View Affiliations / Copyright

    Affiliations: Laboratory of Veterinary Biochemistry and Molecular Biology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 361-763, Republic of Korea, Laboratory of Veterinary Embryology and Biotechnology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 361-763, Republic of Korea, SooAm Biotech Research Foundation, Seoul 137-851, Republic of Korea
  • Pages: 1136-1142
    |
    Published online on: May 20, 2014
       https://doi.org/10.3892/mmr.2014.2255
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Inducible cyclic AMP (cAMP) early repressor (ICER) Iγ acts as an endogenous inhibitor and disrupts the transcriptional regulation of cAMP response element binding protein (CREBP) responsive genes. Since the overexpression of ICER Iγ induces severe diabetes in a transgenic mouse model, with characteristics similar to human diabetes mellitus, an ICER Iγ construct containing an adjustable pancreas tissue specific promoter was utilized in the present study. Using the human insulin promoter region, a doxycycline (dox)‑inducible ICER Iγ expression system was established using the tetracycline (tet)-controlled transactivator (tTA) with a TA response element (TRE) promoter. A unitary tet-on system that combined a tet-on activator cassette was also developed and was controlled by the human insulin promoter with a responder cassette containing genes encoding ICER Iγ regulated by the TRE promoter. To determine whether dox-enhanced ICER Iγ expression affected insulin production, the unitary tet-on ICER Iγ vector was introduced into a mouse pancreatic β-cell line and then the cells were treated with 0.1-1 mg/ml dox. The results revealed a robust increase in ICER Iγ expression and decreased insulin production. Therefore, this in vitro system may be useful for studying human diabetes mellitus and pre-diabetes using tissue-specific promoters and a dox-inducible transgene. In addition, porcine transgenic fibroblasts containing dox-inducible ICER Iγ were generated. These fibroblasts may serve as a cell source for somatic cell nuclear transfer to generate a porcine model of human diabetes mellitus.

Introduction

The expression of insulin genes in pancreatic islet cells is affected by plasma glucose or intracellular cAMP (1,2). cAMP response element binding protein (CREBP) stimulates the transcription of insulin genes by binding to CREs in the promoter region (3,4). Among the CREB family members, CRE modulator (CREM) is a unique gene that encodes either transcriptional activators or repressors based on alternative splicing (5). In particular, inducible cAMP early repressor (ICER) has an important role as a dominant-negative regulator of CREB and CREM activity, and consists of DNA binding and leucine zipper domains, while also lacking an N-terminal transactivation domain. As a strong repressor of cAMP-induced gene expression, the ICER acts as an endogenous inhibitor competing with CREB on the CRE sequence, and then ICER Iγ induces the return of cAMP signaling to the basal state (6). Of note, prolonged expression of ICER Iγ results in the development of pathological conditions. Previously, it was reported that the overexpression of ICER Iγ is associated with an increased incidence of diabetes and decreased β-cell numbers in transgenic mice (7,8).

When using constructs with a constitutively active promoter, the unregulated expression of a target gene often produces unexpected results. To avoid these limitations, a conditional transgenic technique was adopted, the tetracycline (tet)-on system. This system enables both temporal and spatial regulation of transgene expression, and requires a responder construct and activator construct in a single cell (9). Transcriptional activator protein (tTA; a transactivator) consists of a modified bacterial tet repressor (TetR) fused to three minimal activation domains of the herpes simplex virus transcription activator (VP16). Expression of this construct is controlled by tetracycline or its analog, doxycycline (dox) (10). In the presence of dox, a conformational change in tTA allows the activator to bind to the tTA-response element (TRE) promoter of a responder construct, and induces transcription of the target gene and a green fluorescent protein reporter gene downstream of the TRE promoter. The TRE promoter consists of seven repeats of a 19-bp tet operator sequence located upstream of a minimal cytomegalovirus (CMV) promoter in which the binding sites for endogenous mammalian transcription factors have been eliminated (11).

In the present study, a pancreas-specific, dox-inducible ICER Iγ expression vector was constructed, where the CMV promoter was exchanged for the human insulin promoter in the activator construct. Additionally, this construct contained a unitary system combined with an activator cassette and responder cassette. Although in vivo experiments designed to study diabetes have been conducted in rodents and other animals (12,13), the phenotypic hallmarks of diabetes mellitus in rodent models are not sufficient to fully elucidate the mechanisms underlying the development of diabetes in humans. Therefore, porcine transgenic fibroblasts were also established, that were genetically modified to evoke type 1 diabetes mellitus-like symptoms in a porcine model.

Materials and methods

Cell culture

The study was approved by the Ethics Committee of Chungbuk National University (Cheongju, Korea). The porcine fibroblasts were obtained from miniature pig fetuses (Yucatan pigs; Optifarm Solution Inc., Gyeonggi-do, Korea) on the thirtieth day of pregnancy and the cells were routinely maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 25 mM glucose, supplemented with 10% fetal bovine serum (FBS; WelGENE, Inc., Daejeon, South Korea), 100 U/ml penicillin and 100 μg/ml streptomycin. The mouse β-cell line, MIN6 (American Type Culture Collection, Manassas, VA, USA), was cultured in DMEM containing 25 mM glucose, supplemented with 15% FBS, 55 μM 2-mercaptoethanol (Gibco, Grand island, NY, USA), 100 U/ml penicillin and 100 μg/ml streptomycin. All cells were grown in a humidified 5% CO2 atmosphere at 37°C. Unless otherwise indicated, all cell culture materials were obtained from Invitrogen Life Technologies (Carlsbad, CA, USA).

Genomic DNA extraction and PCR

Genomic DNA from the cells was isolated with a G-DEX™ IIc Genomic DNA Extraction kit (iNtRON Biotechnology, Inc., Seoul, South Korea). Genomic DNA (0.1 μg) was amplified in a 20-μl PCR reaction containing 1 U i-Start Taq polymerase (iNtRON Biotechnology, Inc.), 2 mM dNTPs (Takara Bio, Inc., Shiga, Japan) and 10 pmol of each specific primer. The details of all primers are described in Table I. The PCR reactions were denatured at 94°C for 30 sec, annealed at 62°C for 30 sec and extended at 72°C for 1–2 min. The PCR products were subjected to cloning processes and/or separated on a 1% agarose gel, stained with ethidium bromide and photographed under UV illumination. The image was scanned using GelDoc EQ (Bio-Rad, Hercules, CA, USA).

Table I

Primer sequences.

Table I

Primer sequences.

Primer nameRestriction enzymeDirectionSequences (5′ to 3′)
Human insulin promoter (−1,432)SpeIForwardACT AGT TAC CCC AGG GGC TCA GCC CAG ATG
Human insulin promoter (+1)EcoRIReverseGAA TTC GGC CAG CAG CGC CAG CAG G
ICER Iγ cDNAMluIForwardACG CGT ATG GCT GTA ACT GGA GAT GA
ICER Iγ cDNABamHIReverseGGA TCC CTA ATC TGT TTT AGG AGA GCA AAT G
Tet-response cassetteBst1107IForwardGTA TAC CGA GGC CCT TTC GTC TTC AAG AAT TC
Tet-response cassetteSpeIReverseACT AGT GCC GCA GAC ATG ATA AGA TAC ATT GA
Confirming primer aForwardGTG CTG ACG ACC AAG GAG AT
Confirming primer a′ReverseTTT CAG AAG TGG GGG CAT AG
Confirming primer bForwardGAG GAT GGA GCA GTT TGC AT
Confirming primer b′ReverseGCA TTC CAC CAC TGC TCC CA
ICER IγForwardATG GCT GTA ACT GGA GAT GA
ICER IγReverseCTA ATC TGT TTT AGG AGA GCA AAT G
Insulin-1ForwardCCC TGT TGG TGC ACT TCC TA
Insulin-1ReverseCAC TTG TGG GTC CTC CAC TT
Mouse β-actinForwardACA GGC ATT GTG ATG GAC TC
Mouse β-actinReverseATT TCC CTC TCA GCT GTG GT

[i] ICER Iγ, inducible cyclic AMP early repressor Iγ.

Vector construction

All restriction enzymes were obtained from Takara Bio, Inc. The human insulin promoter region (from nucleotides (nt) −1,431 to +1 nt; +1 = the transcriptional start site) demonstrated the highest transcriptional activity in a previous study (14) and were prepared by long-range PCR using human genomic DNA (Clontech Laboratories, Mountain View, CA, USA) as the template, and specific primers containing restriction enzyme sites (SpeI at the 5′ end or EcoRI at the 3′ end). Amplified fragments were digested with SpeI and EcoRI and replaced with the CMV promoter of the transcriptional activator construct, pCMV-Tet3G, purchased from Clontech Laboratories. The ICER Iγ cDNA was prepared by PCR using genomic DNA from pig pancreas as the template and was inserted into pTRE3G-ZsGreen1 which contains green fluorescence protein, ZsGreen1 (Clontech Laboratories) through MluI at the 5′ end or BamHI at the 3′ end. Using the PCR method, the ICER Iγ-expressing tTA-response region obtained from recombinant pTRE3G-ZsGreen1-pig ICER Iγ construct was digested with Bst1107I or SpeI and combined with the recombinant pHINSP-Tet3G vector controlled by the human insulin promoter.

Establishment of transgenic cell lines

The fibroblasts were transfected with the linearized targeting vector using Lipofectamine® 2000 (Invitrogen, Carlsbad, CA, USA). Following 24 h of transfection, the medium was replaced with DMEM supplemented with 10% FBS and 250 μg/ml G-418 (Roche Diagnostics, Indianapolis, IN, USA) for four weeks. The antibiotic-resistant cells were further selected, subjected to PCR-based genotyping and stored until required for somatic cell nuclear transfer.

Transient transfection and dox treatment

Transient transfection was performed using Lipofectamine™ 2000 according to the manufacturer’s instructions. Briefly, 3×105 cells were seeded in 6-well tissue culture plates one day prior to transfection. In total, 4 μg of the recombinant constructs per well was transfected into the cells under serum-free DMEM. Following incubation for 4 h, the medium was replaced with DMEM containing 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. A total of 20 h later, various concentrations of dox were treated in transiently transfected cells for an additional 24 h.

RNA preparation and semi-quantitative (q)PCR

Total RNA from MIN6 cells was extracted using TRIzol reagent (Invitrogen Life Technologies) according to the manufacturer’s instructions. The concentration of the total RNA was determined by measuring the absorbance at 260 nm. First-strand cDNA was prepared by subjecting total RNA (1 μg) to reverse transcription using Moloney murine leukemia virus (MMLV) reverse transcriptase (Invitrogen Life Technologies) and random primers (9-mers; Takara Bio, Inc.). To determine the optimal conditions for logarithmic phase PCR amplification for target cDNA, aliquots of total cDNA (1 μg) were amplified using different numbers of cycles. The mouse β-actin gene was amplified as the internal control to rule out the possibility of RNA degradation and to control for variations in mRNA concentrations. A linear correlation between PCR product band visibility and the number of amplification cycles was observed for the target mRNA. The mouse β-actin and target genes were quantified using 28 and 30 cycles, respectively. The PCR reactions were denatured at 94°C for 30 sec, annealed at 58°C for 30 sec and extended at 72°C for 30 sec. The PCR products were on a 2.3% agarose gel, stained with ethidium bromide and photographed under UV illumination. The image was scanned using GelDoc EQ (Bio-Rad).

Western blot analysis

Lysates were prepared in RIPA buffer (50 mM Tris, pH 7.4, 150 mM sodium chloride (NaCl), 1% Triton X-100, 0.5% sodium deoxycholate, 1 mM EDTA and 1 mM PMSF) and protease inhibitor cocktail (Roche Diagnostics). Protein content was determined using the Pierce BCA Micro Protein Assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Total proteins obtained by centrifugation (13,000 × g for 20 min at 4°C) were denatured at 95°C for 5 min. A total of 20–50 μg of protein were size-separated by electrophoresis on 13% SDS-polyacrylamide gels and electrophoretically transferred to a nitrocellulose membrane. Non-specific binding was blocked with TBST (20 mM Tris, pH 7.6, 137 mM NaCl and 0.05% Tween-20) containing 5% non-fat milk for 2 h at room temperature (RT). The membrane was probed with the following primary antibodies for 2 h at RT: rabbit polyclonal antibody to Insulin (H-86, sc-9168), diluted 1:1,000; rabbit polyclonal antibody to CREM (X-12, sc-440), diluted 1:1,000 and rabbit polyclonal antibody to β-actin (N-21, sc-130656), diluted 1:1,000. All antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The membrane was subsequently exposed to a horseradish peroxidase-conjugated secondary antibody (1:5,000 dilution in TBST) for 1 h at RT.

Results

Establishment of a unitary tet-on ICER Iγ expression vector

The unitary tet-on system was composed of an activator cassette and responder cassette (Fig. 1A). The activator cassette had a tTA under the control of the human insulin promoter (−1,432 to +1 nt) which is associated with maximum promoter activity in mouse MIN6 β-cells line according to our previous study (14). The responder cassette contained the porcine ICER Iγ target gene and cDNA encoding ZsGreen1 green fluorescence protein. The expression of both genes was controlled by a TRE promoter. tTA was specifically transcribed in pancreas cells under the control of the human insulin promoter, underwent a conformational change induced by the administration of dox and then bound to the TRE promoter of the responder cassette. Finally, the key gene downstream of the TRE promoter, ICER Iγ, was specifically transcribed in the pancreas cells. Additionally, expression of the green fluorescence marker, ZsGreen1, was observed.

Figure 1

Schematic structure of the targeting vector and PCR-based confirmation of transgenic fibroblasts. (A) The unitary tet-on system was composed of two parts in a vector; an activator cassette and a responder cassette. The activator cassette had tTA under the control of the human insulin promoter (−1,432 to +1 nt). The responder cassette contained the target gene, porcine ICER Iγ and ZsGreen1 cDNA expressing green fluorescence protein, both which are controlled by the TRE promoter. This unitary vector was linearized and integrated into the genomic DNA of the porcine fibroblasts. Genomic DNA was isolated from G418-resistant fibroblast colonies and was identified with specific primer sets indicated by the arrows (a, a′, b, b′). (B) The PCR products with primer a and a′ represents the chromosomal insertion of the activator cassette. (C) Whether the same fibroblast colonies had responder cassette was confirmed using primer b and b′. IRES, internal ribosomal entry site; SM, size marker; NC, negative control; ICER Iγ, inducible cyclic AMP early repressor Iγ; tTa, tet-controlled transactivator; TRE, tTA-response element.

Generation and characterization of fibroblast cell lines containing the dox-inducible porcine ICER Iγ construct

The dox-inducible porcine ICER Iγ vector was linearized and used to transfect miniature pig fibroblasts using a liposomal-mediated gene delivery system. The transfected fibroblasts were selected and maintained with a medium containing G418 (250 μg/ml) for four weeks. Chromosomal integration of the targeting vector was confirmed by a PCR-based method using primer sets specific for the vector (Table I). Genomic DNA extracted from G418-resistant colonies was amplified with primers a and a′ (product size, 992 bp; Fig. 1B) or primers b and b′ (product size, 1,585 bp; Fig. 1C). In total, 12 positive colonies were obtained following two rounds of transfection (Table II). Fibroblasts from the positive colonies may serve as a cellular source for somatic cell nuclear transfer to generate a porcine model that overexpresses ICER Iγ in a dox-inducible, pancreas-specific manner.

Table II

Transfection efficiencies of the porcine fibroblasts.

Table II

Transfection efficiencies of the porcine fibroblasts.

Colony (n)

Transfection trials (n)G418 resistantPCR positive
21212
Observation of dox-inducible fluorescence in MIN6 cells and porcine fibroblasts

To observe tissue-specific expression, we transiently transfected mouse pancreatic β-cells (MIN6) and porcine non-pancreatic fibroblasts. The cells were co-transfected with pCMV-TA and pTRE-ZsGreen1-ICER Iγ constructs as a positive control to confirm the activity of the dox-inducible expression system. In the MIN6 cells expressing pHINSP-TA-TRE-ZsGreen-ICER Iγ, we observed green fluorescence indicative of dox-inducible and pancreas-specific ICER Iγ expression (Fig. 2). In this regard, green fluorescence was also confirmed following dox treatment in a dose-dependent manner (0, 0.1 and 1 μg/ml). However, no fluorescence was observed in either the untreated or dox-treated porcine fibroblasts transiently transfected with pHINSP-TA-TRE-ZsGreen-ICER Iγ due to the pancreas specific insulin promoter (Fig. 3).

Figure 2

Observation of dox-inducible green fluorescence in mouse β-cell line, MIN6, by transient transfection of pCMV-TA with (A) pTRE-ZsGreen-ICER Iγ or (B) unitary pHINSP-TA-TRE-ZsGreen-ICER Iγ. In the MIN6 cell line, dox-inducible and pancreas specific expression of green fluorescence by human insulin promoter was observed. Furthermore, the green fluorescence demonstrated dox-dose dependent expression, as treated dox concentration was increased to 0, 0.1 and 1 mg/ml. CMV, cytomegalovirus promoter; TA, tet-on transcription activator; HINSP, human insulin promoter; ICER Iγ, inducible cyclic AMP early repressor Iγ; TRE, tTA-response element.

Figure 3

Observation of dox-inducible green fluorescence in porcine fibroblasts by transient transfection of pCMV-TA with (A) pTRE-ZsGreen-ICER Iγ or (B) unitary pHINSP-TA-TRE-ZsGreen-ICER Iγ. Treated dox concentration was increased to 0, 0.1 and 1 mg/ml. CMV, cytomegalovirus promoter; TA, tet-on transcription activator; HINSP, human insulin promoter; ICER Iγ, inducible cyclic AMP early repressor Iγ; TRE, tTA-response element; dox, doxycycline.

Dox-inducible porcine ICER Iγ mRNA expression in mouse β-cells

To evaluate dox-inducible ICER Iγ expression under the control of the human insulin promoter, reverse transcription (RT)-PCR was performed using mRNA obtained from transiently transfected MIN6 cells and porcine fibroblasts. Consistent to the fluorescence microscopy findings, dox-dose dependent and pancreas specific mRNA expression of ICER Iγ was observed in MIN6 cells (Fig. 4A) following dox treatment but not in porcine fibroblasts (data not presented). Additionally, the expression levels of ICER Iγ in cells transfected with only pCMV-TA or pTRE-ZsGreen1-ICER Iγ were unchanged regardless of the absence or presence of dox. Although ICER Iγ expression in MIN6 cells expressing the pTRE-ZsGreen1-ICER Iγ transgene was observed, the level was consistently low and unaffected regardless of the presence of dox. It should be considered that unknown factors of the transcriptional environment may regulate the gene expression of in vitro systems through introduction of the target gene.

Figure 4

Dox-inducible porcine ICER Iγ mRNA and protein expression in the mouse β-cell line, MIN6. (A) Dox-dose dependent mRNA overexpression of ICER Iγ in both pCMV-TA with pTRE-ZsGreen-ICER Iγ and pHINSP-TA-TRE-ZsGreen-ICER Iγ transiently transfected MIN6 cells using RT-PCR. (B) ICER Iγ-protein overexpression by dox administration revealed downregulation of insulin in MIN6 cells using western blot analysis. CMV, cytomegalovirus promoter; TA, tet-on transcription activator; HINSP, human insulin promoter; ICER Iγ, inducible cyclic AMP early repressor Iγ; TRE, tTA-response element; dox, doxycycline; RT-PCR, reverse transcription-PCR.

Insulin production in mouse β-cells expressing the dox-inducible porcine ICER Iγ gene

Since the ICER Iγ transgene represses insulin production in vivo (7,8), western blot analysis was performed to determine whether dox-inducible expression of porcine ICER Iγ may inhibit insulin generation. The expression of insulin was evaluated in transiently transfecting MIN6 cells with four combinations of the constructs (Fig. 4B). ICER Iγ protein in cells transfected with only pCMV-TA or pTRE-ZsGreen1-ICER Iγ was not expressed regardless of the absence or presence of dox. Dox-inducible expression of ICER Iγ was observed in cells co-transfected with pCMV-TA and pTRE-ZsGreen1-ICER Iγ, or transfected with pHINSP-TA-TRE-ZsGreen1-ICER Iγ alone. By contrast, insulin expression was decreased in the presence of dox. These findings indicated that dox-inducible ICER Iγ expression decreases insulin expression in mouse pancreas β-cell. Therefore, the extensive induction of ICER Iγ expression may interfere with insulin synthesis and promote the development of type 1 diabetes mellitus. As a result, our dox-inducible ICER Iγ expression system may be a useful tool for studying diabetes mellitus and pre-diabetes in humans by controlling ICER Iγ expression levels through dox administration.

Discussion

In rodent models, it has been reported that ICERs have an important role in T-cell mediated downregulated expression of interleukin (IL)-2, an essential growth factor for auto-aggressive T-effector cells (15,16). In pancreatic β-cells, ICER Iγ suppresses not only insulin gene transcription but also cell replication via the reduction of cyclin A levels (7,17). Therefore, the prolonged or constitutive expression of ICER results in the development of pathological conditions (7) similar to severe cases of diabetes mellitus, because ICER Iγ overexpression significantly blocks CRE-mediated transcription by competing with CRE-binding activators (6,18). Therefore, in the present study, a tissue-specific ICER Iγ vector was constructed, whose expression was controlled by dox, and a porcine fibroblast cell line with this construct was also established to generate transgenic piglets.

The insulin promoter directly regulates insulin gene transcription according to plasma glucose levels and enables β-cells to produce insulin (19,20). On this basis, the insulin promoter was utilized in the present study as a β-cell-specific regulator of gene transcription. The human insulin promoter region spanning −1,431 to +1 nt significantly increased ICER Iγ gene expression in MIN6 cells in the presence of high glucose levels and dox (Fig. 4A). However, induction of ICER Iγ expression in MIN6 cells slightly downregulated insulin production (Fig. 4B). It was hypothesized that the activity of the porcine ICER Iγ protein would not be maximized in mouse β-cells because the porcine ICER Iγ protein is documented as having 92.6–94.4% identity to mouse ICERs, using a BLAST tool. By contrast, it may be possible to reduce the interaction between porcine ICER Iγ and mouse insulin promoter regulatory elements.

It was reported that the relative number and composition of principal insulin promoter regulatory elements in different species was determined through transcription factor binding site turnover and accretion (21–23). In particular, CRE is a key determinant of gene expression (24,25) and binds to the widest array of transcription factors in the insulin promoter (26). Unlike the human insulin promoter that contains four copies of CREs, the mouse insulin promoter only has a single copy (23). For this reason, the binding rate of overexpressed ICER Iγ within the mouse insulin promoter may decrease and the repression of insulin expression by ICER Iγ may be weaker in spite of ICER Iγ overexpression via the human insulin promoter in mouse β-cells.

MIN6 cells were derived from a transgenic C57BL/6 mouse insulinoma expressing an insulin-promoter/T-antigen construct and possess characteristics of pancreatic β-cells, including the ability to secrete insulin in response to glucose (27,28). Although the amount of insulin secreted from MIN6 cells in the presence of a high (25 mM) glucose concentration is six-to seven-fold greater than that observed with a low (5 mM) glucose level, it has been noted that glucose-induced insulin secretion from the MIN6 cells may suddenly be lost during the course of passaging (28). This may result in a poor response to the downregulation of glucose-mediated insulin production via dox-inducible ICER Iγ expression.

To generate a porcine model for diabetes or metabolic syndromes, pig fibroblast cell lines expressing dox-inducible ICER Iγ were established. These cells should be a useful source for somatic cell nuclear transfer procedures. Porcine models provide various advantages for studying human metabolic syndromes because pigs are mono-gastric omnivores and have anatomical/physiological characteristics similar to that of humans (29). The porcine model established using the created cells may offer information crucial for understanding the mechanisms underlying human diabetes mellitus.

In the present study, the dox-inducible, tissue-specific expression of the transcriptional repressor ICER Iγ was observed in a mouse pancreatic β-cell line. This result was compared with the expression of ICER Iγ observed in transiently transfected primary porcine fibroblasts. The unitary tet-on ICER Iγ induction system was pancreas-specific and dox-inducible. When generating transgenic animals, these cellular traits may reduce stillbirth rates during pregnancy and unwanted outcomes caused by uncontrollable gene expression.

Acknowledgments

This study was supported by a grant from the Next-Generation BioGreen 21 Program (no. PJ00956301), Rural Development Administration, Republic of Korea.

References

1 

Leonard J, Serup P, Gonzalez G, Edlund T and Montminy M: The LIM family transcription factor Isl-1 requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells. Proc Natl Acad Sci USA. 89:6247–6251. 1992. View Article : Google Scholar

2 

Barnett DW, Pressel DM, Chern HT, Scharp DW and Misler S: cAMP-enhancing agents ‘permit’ stimulus-secretion coupling in canine pancreatic islet beta-cells. J Membr Biol. 138:113–120. 1994.

3 

Ortmeyer HK: Insulin decreases skeletal muscle cAMP-dependent protein kinase (PKA) activity in normal monkeys and increases PKA activity in insulin-resistant rhesus monkeys. J Basic Clin Physiol Pharmacol. 8:223–235. 1997. View Article : Google Scholar : PubMed/NCBI

4 

Seino S, Takahashi H, Fujimoto W and Shibasaki T: Roles of cAMP signalling in insulin granule exocytosis. Diabetes Obes Metab. 11(Suppl 4): 180–188. 2009. View Article : Google Scholar

5 

Foulkes NS, Borrelli E and Sassone-Corsi P: CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell. 64:739–749. 1991. View Article : Google Scholar : PubMed/NCBI

6 

Mioduszewska B, Jaworski J and Kaczmarek L: Inducible cAMP early repressor (ICER) in the nervous system - a transcriptional regulator of neuronal plasticity and programmed cell death. J Neurochem. 87:1313–1320. 2003. View Article : Google Scholar : PubMed/NCBI

7 

Inada A, Hamamoto Y, Tsuura Y, Miyazaki J, Toyokuni S, Ihara Y, Nagai K, Yamada Y, Bonner-Weir S and Seino Y: Overexpression of inducible cyclic AMP early repressor inhibits transactivation of genes and cell proliferation in pancreatic beta cells. Mol Cell Biol. 24:2831–2841. 2004. View Article : Google Scholar : PubMed/NCBI

8 

Inada A, Someya Y, Yamada Y, Ihara Y, Kubota A, Ban N, Watanabe R, Tsuda K and Seino Y: The cyclic AMP response element modulator family regulates the insulin gene transcription by interacting with transcription factor IID. J Biol Chem. 274:21095–21103. 1999. View Article : Google Scholar : PubMed/NCBI

9 

Gossen M and Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 89:5547–5551. 1992. View Article : Google Scholar : PubMed/NCBI

10 

Zhou X, Vink M, Klaver B, Berkhout B and Das AT: Optimization of the Tet-On system for regulated gene expression through viral evolution. Gene Ther. 13:1382–1390. 2006. View Article : Google Scholar : PubMed/NCBI

11 

Gossen M, Freundlieb S, Bender G, Müller G, Hillen W and Bujard H: Transcriptional activation by tetracyclines in mammalian cells. Science. 268:1766–1769. 1995. View Article : Google Scholar : PubMed/NCBI

12 

Saudek F: Gene therapy in the treatment of diabetes mellitus. Cas Lek Cesk. 142:523–527. 2003.(In Czech).

13 

Driver JP, Serreze DV and Chen YG: Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol. 33:67–87

14 

Jung EM, Kim YK, Lee GS, Hyun SH, Hwang WS and Jeung EB: Establishment of inducible cAMP early repressor transgenic fibroblasts in a porcine model of human type 1 diabetes mellitus. Mol Med Rep. 6:239–245

15 

Bodor J, Fehervari Z, Diamond B and Sakaguchi S: ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur J Immunol. 37:884–895. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Bodor J, Spetz AL, Strominger JL and Habener JF: cAMP inducibility of transcriptional repressor ICER in developing and mature human T lymphocytes. Proc Natl Acad Sci USA. 93:3536–3541. 1996. View Article : Google Scholar : PubMed/NCBI

17 

Inada A, Weir GC and Bonner-Weir S: Induced ICER Igamma down-regulates cyclin A expression and cell proliferation in insulin-producing beta cells. Biochem Biophys Res Commun. 329:925–929. 2005. View Article : Google Scholar : PubMed/NCBI

18 

Molina CA, Foulkes NS, Lalli E and Sassone-Corsi P: Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell. 75:875–886. 1993. View Article : Google Scholar

19 

Odagiri H, Wang J and German MS: Function of the human insulin promoter in primary cultured islet cells. J Biol Chem. 271:1909–1915. 1996. View Article : Google Scholar : PubMed/NCBI

20 

Burkhardt BR, Loiler SA, Anderson JA, Kilberg MS, Crawford JM, Flotte TR, Goudy KS, Ellis TM and Atkinson M: Glucose-responsive expression of the human insulin promoter in HepG2 human hepatoma cells. Ann NY Acad Sci. 1005:237–241. 2003. View Article : Google Scholar : PubMed/NCBI

21 

Rockman MV and Wray GA: Abundant raw material for cis-regulatory evolution in humans. Mol Biol Evol. 19:1991–2004. 2002. View Article : Google Scholar : PubMed/NCBI

22 

Ludwig MZ and Kreitman M: Evolutionary dynamics of the enhancer region of even-skipped in Drosophila. Mol Biol Evol. 12:1002–1011. 1995.PubMed/NCBI

23 

Hay CW and Docherty K: Comparative analysis of insulin gene promoters: implications for diabetes research. Diabetes. 55:3201–3213. 2006. View Article : Google Scholar : PubMed/NCBI

24 

Daniel PB, Walker WH and Habener JF: Cyclic AMP signaling and gene regulation. Annu Rev Nutr. 18:353–383. 1998. View Article : Google Scholar : PubMed/NCBI

25 

Inagaki N, Maekawa T, Sudo T, Ishii S, Seino Y and Imura H: c-Jun represses the human insulin promoter activity that depends on multiple cAMP response elements. Proc Natl Acad Sci USA. 89:1045–1049. 1992. View Article : Google Scholar : PubMed/NCBI

26 

Foulkes NS and Sassone-Corsi P: Transcription factors coupled to the cAMP-signalling pathway. Biochim Biophys Acta. 1288:F101–F121. 1996.PubMed/NCBI

27 

Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, Anai M, Kikuchi M, Yazaki Y, Miyazaki JI and Oka Y: Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia. 36:1139–1145. 1993. View Article : Google Scholar

28 

Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y, Oka Y and Yamamura K: Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology. 127:126–132. 1990. View Article : Google Scholar

29 

Petersen B, Carnwath JW and Niemann H: The perspectives for porcine-to-human xenografts. Comp Immunol Microbiol Infect Dis. 32:91–105. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Kang HY, Jung E, Hong E, Hyun S, Hwang W and Jeung E: Generation of transgenic fibroblasts expressing pancreas‑specific and doxycycline-inducible ICER Iγ for the establishment of a porcine model of human diabetes mellitus. Mol Med Rep 10: 1136-1142, 2014.
APA
Kang, H.Y., Jung, E., Hong, E., Hyun, S., Hwang, W., & Jeung, E. (2014). Generation of transgenic fibroblasts expressing pancreas‑specific and doxycycline-inducible ICER Iγ for the establishment of a porcine model of human diabetes mellitus. Molecular Medicine Reports, 10, 1136-1142. https://doi.org/10.3892/mmr.2014.2255
MLA
Kang, H. Y., Jung, E., Hong, E., Hyun, S., Hwang, W., Jeung, E."Generation of transgenic fibroblasts expressing pancreas‑specific and doxycycline-inducible ICER Iγ for the establishment of a porcine model of human diabetes mellitus". Molecular Medicine Reports 10.2 (2014): 1136-1142.
Chicago
Kang, H. Y., Jung, E., Hong, E., Hyun, S., Hwang, W., Jeung, E."Generation of transgenic fibroblasts expressing pancreas‑specific and doxycycline-inducible ICER Iγ for the establishment of a porcine model of human diabetes mellitus". Molecular Medicine Reports 10, no. 2 (2014): 1136-1142. https://doi.org/10.3892/mmr.2014.2255
Copy and paste a formatted citation
x
Spandidos Publications style
Kang HY, Jung E, Hong E, Hyun S, Hwang W and Jeung E: Generation of transgenic fibroblasts expressing pancreas‑specific and doxycycline-inducible ICER Iγ for the establishment of a porcine model of human diabetes mellitus. Mol Med Rep 10: 1136-1142, 2014.
APA
Kang, H.Y., Jung, E., Hong, E., Hyun, S., Hwang, W., & Jeung, E. (2014). Generation of transgenic fibroblasts expressing pancreas‑specific and doxycycline-inducible ICER Iγ for the establishment of a porcine model of human diabetes mellitus. Molecular Medicine Reports, 10, 1136-1142. https://doi.org/10.3892/mmr.2014.2255
MLA
Kang, H. Y., Jung, E., Hong, E., Hyun, S., Hwang, W., Jeung, E."Generation of transgenic fibroblasts expressing pancreas‑specific and doxycycline-inducible ICER Iγ for the establishment of a porcine model of human diabetes mellitus". Molecular Medicine Reports 10.2 (2014): 1136-1142.
Chicago
Kang, H. Y., Jung, E., Hong, E., Hyun, S., Hwang, W., Jeung, E."Generation of transgenic fibroblasts expressing pancreas‑specific and doxycycline-inducible ICER Iγ for the establishment of a porcine model of human diabetes mellitus". Molecular Medicine Reports 10, no. 2 (2014): 1136-1142. https://doi.org/10.3892/mmr.2014.2255
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team